© 2002 by Oxford University Press
Journal of the National Cancer Institute, Vol. 94, No. 14, 1050-1052,
July 17, 2002
© 2002 Oxford University Press
NEWS |
Can Increased Treatment of Hepatitis C Stem the Tide of Liver Cancer?
| The first 10% of the full text of this article appears below. |
Reflecting concern at a projected fourfold increase in the prevalence of chronic hepatitis C infection in the next decade, a National Institutes of Health-sponsored advisory panel has recommended that previously ineligible patients receive the latest combination drug therapy designed to clear the virus from blood.
This recommendation and several others were the product of a consensus conference in June convened to update a 1997 report on the management of hepatitis C. The recommendations in the earlier statement excluded several patient groups because there was little information about the efficacy of treatment. But recent studies suggest more patients could be helped by the newer therapies now available. Nevertheless, experts question whether broader treatment efforts will ultimately have an effect on one of the most serious
Chronic Infection
Cancer Development
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. I. Capurro, Y.-Y. Xiang, C. Lobe, and J. Filmus Glypican-3 Promotes the Growth of Hepatocellular Carcinoma by Stimulating Canonical Wnt Signaling Cancer Res., July 15, 2005; 65(14): 6245 - 6254. [Abstract] [Full Text] [PDF]
|
|